All In Biotech

Drug Trial Radar · NCT07748039

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,440

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Mar 1, 2029

Study completion Aug 1, 2029

Sponsor

Lead sponsor
Yongjun WangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute ischemic stroke caused by large vessel occlusion (LVO) is a major cause of disability, and mechanical thrombectomy (MT) has become the standard treatment for eligible patients. However, the optimal role of intravenous thrombolysis before MT remains uncertain. The TRACE-BRIDGE trial is a phase 3, investigator-initiated, multicenter, randomized, open-label trial with blinded outcome assessment (PROBE design) evaluating different bridging thrombolysis strategies before MT. The trial will enroll adults with acute ischemic stroke presenting within 4.5 hours of symptom onset and with imaging-confirmed anterior circulation LVO who are eligible for intravenous thrombolysis and MT. Participants will be randomly assigned in a 1:1:1 ratio to receive tenecteplase plus MT, reteplase plus MT, or direct MT alone. The TRACE-BRIDGE trial aims to evaluate the efficacy and safety of bridging thrombolysis with tenecteplase or reteplase before mechanical thrombectomy compared with direct mechanical thrombectomy. The primary outcome is functional independence, defined as a modified Rankin Scale score of 0-2 at 90 days after randomization. If superiority of bridging thrombolysis is demonstrated, the trial will further evaluate whether reteplase is non-inferior to tenecteplase as a bridging thrombolytic strategy.

Conditions

  • Acute Ischemic Stroke
  • Large Vessel Occlusion
  • Anterior Circulation Brain Infarction

Interventions

  • rhTNK-tPA (0.25mg/kg)Drug

    Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) administered as a single intravenous bolus at a dose of 0.25 mg/kg (maximum dose 25 mg) within 4.5 hours of symptom onset prior to mechanical thrombectomy.

  • Reteplase 10 Units (U) plus a second dose of reteplase 10 UDrug

    Two intravenous bolus injections of 18 mg each, administered within 4.5 hours of onset over approximately 2 minutes per bolus, separated by a 30-minute interval prior to thrombectomy. To avoid delays in reperfusion therapy, groin puncture and MT procedures may be initiated after administration of the first 18 mg bolus, without waiting for completion of the second bolus. Unless contraindicated, the second rPA bolus should be administered according to the scheduled dosing regimen irrespective of EVT status.

  • No thrombolysis (thrombectomy alone)Procedure

    Patients will undergo mechanical thrombectomy according to standard practice, without administration of intravenous thrombolytic agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional IndependenceTime frame: From randomization to 90 days after randomization (±7 days), with outcome assessment performed by blinded assessors.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical Universiity

    Beijing, Beijing Municipality, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China · Not yet recruiting

  • Rizhao Hospital of Traditional Chinese Medicine

    Rizhao, Shandong, China · Not yet recruiting

  • Ya'an People's Hospital

    Ya'an, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.